SNCA and Parkinson disease: To elucidate whether ZNS has potential as a neuroprotective agent for the treatment of Parkinson’s disease, the present study focused on the effects of ZNS on α-synuclein-induced loss of nigrostriatal dopamine neurons and α-synuclein aggregation in a rat model, which expressed A53T α-synuclein using rAAV2.